SCHEMBL5106115

SCHEMBL5106115

CC(C)n1c(=O)n(C)c(=O)c2c(C(=O)O)c(Cc3cnn(-c4ccccc4)c3)sc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A1 P53985 9/20 0.49
ERCC5 P28715 5/20 0.41
HPGDS O60760 1/20 0.37
ALKBH2 Q6NS38 1/20 0.37
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
FEN1 P39748 2/20 0.36
CYP2C9 P11712 3/20 0.35
CYP3A4 P08684 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
NR4A1 P22736 1/20 0.35
MPI P34949 1/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5093441 0.90 SLC16A1 (0.45) SLC16A1ERCC5MAPTMEN1KMT2A
SCHEMBL5097085 0.84 SLC16A1 (0.40) SLC16A1CYP2C9CYP3A4
SCHEMBL5093460 0.78 SLC16A1 (0.46) SLC16A1CYP2C9CYP3A4
SCHEMBL5097135 0.78 SLC16A1 (0.48) SLC16A1CYP2C9CYP3A4
SCHEMBL5097079 0.78 SLC16A1 (0.48) SLC16A1MEN1KMT2ACYP2C9CYP3A4
Hydrochloric Acid SCHEMBL5099848 0.77 SLC16A1 (0.47) SLC16A1CYP2C9CYP3A4
SCHEMBL5106175 0.74 SLC16A1 (0.49) SLC16A1CYP2C9CYP3A4KDM4E
SCHEMBL5096942 0.74 SLC16A1 (0.38) SLC16A1MAPTMEN1KMT2ALMNA
SCHEMBL5097011 0.73 SLC16A1 (0.47) SLC16A1CYP2C9CYP3A4
SCHEMBL5106763 0.72 SLC16A1 (0.46) SLC16A1MEN1KMT2ACYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214579-A1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE ASTRAZENECA AB (SE) 2008-09-04 US disclosed
US-7384951-B2 Thienopyrimidinediones and their use in the modulation of autoimmune disease ASTRAZENECA AB (SE) 2008-06-10 US disclosed
EP-1587812-B1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE ASTRAZENECA AB (SE) 2006-08-09 EP disclosed
US-20060052400-A1 Thienopyriminediones and their use in the modulation of autoimmune disease ASTRAZENECA AB (SE) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214579-A1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE TPMT, TYMP, TYMS SLC16A1 3968/4885ERCC5 833/4885HPGDS 313/4885
US-20060052400-A1 Thienopyriminediones and their use in the modulation of autoimmune disease C5, HRH4, CYP2S1 SLC16A1 4250/4885ERCC5 1966/4885HPGDS 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.